Global CNS Specific Antisense Oligonucleotide Market Analysis
Antisense oligonucleotide plays an important role in modern healthcare, because it acts on the messenger RNA level before the protein is formed to inhibit expression of specific diseases-causing genes.
Global CNS Specific Antisense Oligonucleotide Market: Drivers
Increasing rate of cancer is likely to boost growth of the global CNS specific antisense oligonucleotide market. CNS specific antisense oligonucleotide is utilized for treat neurodegenerative disease and related rare diseases. As per the National Center for Biotechnology Information (NCBI) February 2017 report, the incidence of cerebral palsy is above 1.5 to 4 per 1,000 children aged 10-14 years. The number of births of cerebral palsy is 2 per 1,000 live births worldwide.
Get Sample Report with Latest Covid19 Impact Analysis @ https://www.coherentmarketinsights.com/insight/request-sample/2477
Moreover, the launch of new products for the rare disease related to CNS disorders has led to growth in the global CNS specific antisense oligonucleotide market over the estimated period. For example, Ionis Pharmaceuticals, Inc. and Akcea Therapeutics, Inc. has been approved by the US Food and Drug Administration (FDA) in October 2018, for his new drug TEGSEDITM (inotersen), which is indicated for the treatment of polyneuropathy of genetic transthyretin-mediated amyloidosis. In adults. That same year, the Canadian Health Authority approved the company for a new drug i.e. TEGSEDITM (inotersen).
Global CNS Specific Antisense Oligonucleotide Market: Key Takeaways
Rich product pipeline for the treatment of neurodegenerative disorder is likely to propel the growth of the market. For example, in October 2017, Ionis Pharmaceuticals, Inc. began Phase 1/2 clinical study of IONIS-MAPTRx in patients with mild Alzheimer’s disease. Biogen pays US$10 million milestone to Ionis Pharmaceuticals, Inc.
In addition, key players in the sport focus on getting the US Food and Drug Administration (FDA) approval for new products to reduce the burden of CNS-related disorders. For example, in September 2016, Sarepta Therapeutics moved to the U.S. The Food and Drug Administration (FDA) has approved Exondys 51 (eteplirsen) for the treatment of the rare genetic disorder Duchenne Muscular Dystrophy.
The size of the global CNS specific antisense oligonucleotide market is US$ 883.7 million in 2017, and during the estimated period (2018-2026) it is likely to witness a CAGR of 24.9%.
Global CNS Specific Antisense Oligonucleotide Market: Key Restraints
However, the expensive treatment and the risk of toxicity are liked to obstruct market growth. As per the journal Molecular Therapy, Biogen priced Spinraza (Nusinerson injections) at US$ 750,000 (US$ 125,000 per injection) and US$ 350,000 annually for first year treatments in May 2017.
Get PDF Brochure with Latest Insights @ https://www.coherentmarketinsights.com/insight/request-pdf/2477
Global CNS Specific Antisense Oligonucleotide Market: Regional Analysis
Government support for the development and launch of antisense drugs in North America is likely to drive market growth. North America secures the leading position in the global CNS specific antisense oligonucleotide market due to strong government support for antisense drugs. For example, GeneTx Biotherapeutics LLC’s, GTX-101 was launched in the U.S. for GTX-101 in March 2018, for the treatment of Angelman syndrome. It is a rare neurogenetic disease that infects one in 15,000 people, according to the FDA.
The growing rate of Alzheimer’s disease is likely to drive the market growth. For example, the National Center for Biotechnology Information (NCBI) listed Alzheimer’s disease as the most repeated reason for dementia in Western societies in August 2012, with an estimated 5.5 million cases in the US and an estimated 24 million cases worldwide.
Global CNS Specific Antisense Oligonucleotide Market: Segmentation
On the basis of Drug, the Global CNS Specific Antisense Oligonucleotide Market is segmented into:
- Approved
- Pipeline
On the basis of Indication, the Global CNS Specific Antisense Oligonucleotide Market is segmented into:
- Hereditary Transthyretin Amyloidosis (hATTR)/Polyneuropathy
- Spinal Muscular Atrophy
- Huntington’s Disease
On the basis of Distribution Channel, the Global CNS Specific Antisense Oligonucleotide Market is segmented into:
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
On the basis of Region, the Global CNS Specific Antisense Oligonucleotide Market is segmented into:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East
- Africa
Global CNS Specific Antisense Oligonucleotide Market: Competitive Landscape
Key players performing in the global CNS specific antisense oligonucleotide market are Q-STATE BIOSCIENCES Inc., ProQR Therapeutics N.V., Dynacure, Stroke Therapeutics Inc., Wave Life Sciences Ltd., Ionis Pharmaceuticals Inc., Biogen Inc., Sarepta Therapeutics Inc., and Alnylam Pharmaceuticals Inc.
𝗕𝘂𝘆 𝗡𝗼𝘄 𝗧𝗼 𝗚𝗲𝘁 𝗙𝗹𝗮𝘁 30% 𝗢𝗳𝗳
Purchase This Premium Report To Access Full Information @ https://www.coherentmarketinsights.com/insight/buy-now/2477
Table of Content
Chapter 1 Industry Overview
1.1 Definition
1.2 Assumptions
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Global CNS Specific Antisense Oligonucleotide Market Size Analysis from 2021 to 2027
11.6 COVID-19 Outbreak: CNS Specific Antisense Oligonucleotide Industry Impact
Chapter 2 Global CNS Specific Antisense Oligonucleotide Competition by Types, Applications, and Top Regions and Countries
2.1 Global CNS Specific Antisense Oligonucleotide (Volume and Value) by Type
2.3 Global CNS Specific Antisense Oligonucleotide (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Global CNS Specific Antisense Oligonucleotide Sales, Consumption, Export, Import by Regions (2016-2021)
Chapter 5 North America CNS Specific Antisense Oligonucleotide Market Analysis
Chapter 6 East Asia CNS Specific Antisense Oligonucleotide Market Analysis
Chapter 7 Europe CNS Specific Antisense Oligonucleotide Market Analysis
Chapter 8 South Asia CNS Specific Antisense Oligonucleotide Market Analysis
Chapter 9 Southeast Asia CNS Specific Antisense Oligonucleotide Market Analysis
Chapter 10 Middle East CNS Specific Antisense Oligonucleotide Market Analysis
Chapter 11 Africa CNS Specific Antisense Oligonucleotide Market Analysis
Chapter 12 Oceania CNS Specific Antisense Oligonucleotide Market Analysis
Chapter 13 South America CNS Specific Antisense Oligonucleotide Market Analysis
Chapter 14 Company Profiles and Key Figures in CNS Specific Antisense Oligonucleotide Business
Chapter 15 Global CNS Specific Antisense Oligonucleotide Market Forecast (2021-2027)
Chapter 16 Conclusions
Research Methodology
Continued….
Talk To Our Expert: https://www.coherentmarketinsights.com/insight/talk-to-analyst/2477
About Us:
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837